Other languages Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Delayed OTC Markets Other stock markets 01:32:41 2024-04-26 pm EDT			5-day change	1st Jan Change
3.08 ^USD	+13.65%		+18.46%	+254.02%

Apr. 24	Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	CI
Apr. 02	Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	Apr. 24
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	Apr. 02
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	Mar. 19
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	Feb. 14
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	Jan. 29
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	Jan. 05
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	Dec. 14
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	Nov. 09
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23-10-23
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Kiromic Biopharma, Inc. Announces Board Appointments	23-07-24
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed	23-06-30
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Top Premarket Gainers	23-05-03
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer	23-05-01
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17
Kiromic BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16
Sector Update: Health Care Stocks Higher Late Monday	23-04-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Other languages

Filters